A clinical research recruiter at OIC Research talking with a study participant in a consultation room in Orlando

Join a study

Join a clinical study in Orlando at OIC

Join a clinical study in Orlando and be part of the research that shapes the future of medicine, with expert care, at no cost to you.

Participation benefits

What you can expect as a participant

  • Study medications provided at no cost
  • Study-related labs provided at no cost
  • Study-related visits provided at no cost
  • Monitoring by study-related providers
  • Transportation assistance, when needed, through Lyft, Uber, or bus passes
  • Stipend provided at each study visit

Now enrolling

Clinical studies in Orlando currently accepting participants

See full directory
Now enrollingHIV Treatment

Gilead-5938 · Daybreak-1: Twice-Yearly HIV Treatment

Daybreak-1 compares a new, twice-yearly HIV medication combination with an already-approved option given every two months. Group 1 receives two antibody medications, teropavimab and zinlirvimab, together with the antiviral lenacapavir, dosed only twice a year. Group 2 receives cabotegravir and rilpivirine, an injectable combination already used in HIV care, given every 8 weeks. It’s for adults whose HIV is currently well controlled on a daily pill and who are interested in far less frequent dosing. Route: Group 1 takes an oral loading dose on Day 1, then receives the medication by subcutaneous injection and IV infusion; Group 2 receives intramuscular injections. Length: 92 weeks, with an optional 2-year extension phase. Compensation: $100 per completed scheduled or unscheduled visit, $300 for infusion visits. Protocol: GS-US-536-5938 (Daybreak-1) · Phase 3 · Sponsor: Gilead Sciences

I’m interested →
Now enrollingHIV Treatment

Gilead-6544 · Daybreak-2: Twice-Yearly HIV Treatment

Daybreak-2 is a companion study to Daybreak-1, exploring the same twice-yearly medication combination for people whose HIV is already well controlled on a stable daily pill. Group 1 switches to teropavimab and zinlirvimab plus lenacapavir, dosed only twice a year. Group 2 continues on its current stable oral regimen. It’s for adults interested in trying a far less frequent dosing schedule while researchers gather more safety and effectiveness information. Route: Group 1 takes an oral loading dose on Day 1, then receives the medication by subcutaneous injection and IV infusion; Group 2 continues its stable baseline regimen. Length: 92 weeks. Compensation details are provided during screening. Protocol: GS-US-536-6544 (Daybreak-2) · Phase 3 · Sponsor: Gilead Sciences

I’m interested →
Now enrollingHIV Treatment

Gilead-6557 · Pulsar-2: HIV Treatment for Newly Diagnosed Adults

Pulsar-2 is for adults who are newly diagnosed with HIV and haven’t yet started treatment. The study compares an investigational injectable regimen, GS-3242 combined with lenacapavir, with Biktarvy, a daily oral tablet (bictegravir, emtricitabine, and tenofovir alafenamide) that is a standard treatment option today. Researchers want to know whether the injectable regimen controls HIV as well as the daily pill, with less frequent dosing. Route: injectable regimen for the investigational group; daily oral tablet for the comparison group. Length: 52 weeks, with an optional 2-year extension phase. Compensation: $100 per completed scheduled or unscheduled visit, $100 per completed additional injection, $30 per completed phone call visit, and $400 for an optional PK sub-study visit on Day 1. Protocol: GS-US-643-6557 (Pulsar-2) · Phase 2/3 · Sponsor: Gilead Sciences

I’m interested →

Tell us about you

Pre-screening interest form

Name
Race or ethnicity (check all that apply)

Referring a participant?

Are you a provider or community organization? Refer a potential participant to our team and we’ll take care of the rest. Call 407-374-0220 or use the contact form.

Contact us →